or Try an Advanced Search...

    Technical Analysis for CRVO - CervoMed Inc.

    Grade Last Price % Change Price Change
    F 12.81 -6.15% -0.84
    CRVO closed down 6.15 percent on Friday, November 1, 2024, on 69 percent of normal volume.
    Earnings due: Nov 11
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CRVO trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    20 DMA Support Bullish -9.02%
    Crossed Above 20 DMA Bullish -4.97%
    Gapped Up Strength -4.97%
    Fell Below 20 DMA Bearish -2.29%
    Gapped Up Strength -2.29%
    Crossed Above 20 DMA Bullish -6.50%
    MACD Bullish Signal Line Cross Bullish -6.50%
    Up 3 Days in a Row Strength -6.50%
    NR7 Range Contraction 1.91%
    Older End-of-Day Signals for CRVO ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 22 hours ago
    Down 3% about 22 hours ago
    Up 3% about 22 hours ago
    Fell Below Previous Day's Low about 22 hours ago
    Down 2 % about 22 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CRVO Chart by TradingView
    Basic chart:

    Profile

    CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Development Cancer Treatment Oncology Chemotherapy Radiation Ophthalmology Oxygen Dermatology Macular Degeneration Blastoma Radiation Therapy Glioblastoma Signal Transduction Cancer Cell Acne Brain Tumor mTOR Glioblastoma Multiforme Oncology Applications Acne Vulgaris

    Is CRVO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 29 CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
    Oct 15 CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
    Oct 4 CervoMed Ends $20 Million Stock Sales Agreement with BTIG
    Oct 3 CervoMed files for $250M mixed securities shelf
    Oct 2 CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
    Sep 26 CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
    Sep 21 With 35% ownership, insiders at CervoMed Inc. (NASDAQ:CRVO) are pretty optimistic and have been buying recently
    Sep 20 CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?
    Aug 27 CervoMed to Participate in Upcoming Investor Conferences
    Aug 22 CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
    See more CRVO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 26.3789
    52 Week Low 5.85
    Average Volume 82,310
    200-Day Moving Average 16.99
    50-Day Moving Average 14.87
    20-Day Moving Average 13.34
    10-Day Moving Average 13.10
    Average True Range 1.33
    RSI (14) 43.82
    ADX 11.33
    +DI 17.92
    -DI 19.27
    Chandelier Exit (Long, 3 ATRs) 11.01
    Chandelier Exit (Short, 3 ATRs) 15.89
    Upper Bollinger Bands 14.59
    Lower Bollinger Band 12.09
    Percent B (%b) 0.29
    BandWidth 18.70
    MACD Line -0.38
    MACD Signal Line -0.47
    MACD Histogram 0.0943
    Fundamentals Value
    Market Cap 72.69 Million
    Num Shares 5.67 Million
    EPS -5.59
    Price-to-Earnings (P/E) Ratio -2.29
    Price-to-Sales 11.27
    Price-to-Book 5.48
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 15.17
    Resistance 3 (R3) 15.36 14.76 14.77
    Resistance 2 (R2) 14.76 14.16 14.67 14.64
    Resistance 1 (R1) 13.79 13.79 13.49 13.60 14.51
    Pivot Point 13.19 13.19 13.05 13.10 13.19
    Support 1 (S1) 12.22 12.59 11.92 12.03 11.11
    Support 2 (S2) 11.62 12.22 11.53 10.98
    Support 3 (S3) 10.65 11.62 10.85
    Support 4 (S4) 10.46